NCT01588431 2024-02-14
Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer
The University of Texas Health Science Center at San Antonio
Phase 2 Completed
The University of Texas Health Science Center at San Antonio
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
University of Pittsburgh
Case Comprehensive Cancer Center
SCRI Development Innovations, LLC
Duke University